Could Nafamostat or Gabexate Prevent the Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis?.
10.4166/kjg.2012.59.3.232
- Author:
Yong Hwan KWON
1
;
Ji Yeon KIM
;
Sang Jik LEE
;
Se Young JANG
;
Hyun Woo PARK
;
Hae Min YANG
;
Min Kyu JUNG
;
Seong Woo JEON
;
Chang Min CHO
;
Won Young TAK
;
Young Oh KWEON
;
Sung Kook KIM
Author Information
1. Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea. minky1973@Kornet.net
- Publication Type:Original Article ; Controlled Clinical Trial ; English Abstract
- Keywords:
Endoscopic retrograde cholangiopancreatography;
Gabexate;
Nafamostat
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Cholangiopancreatography, Endoscopic Retrograde/*adverse effects;
Female;
Gabexate/*therapeutic use;
Guanidines/*therapeutic use;
Humans;
Male;
Middle Aged;
Pancreatitis/etiology/*prevention & control;
Placebo Effect;
Questionnaires;
Serine Proteinase Inhibitors/*therapeutic use;
Young Adult
- From:The Korean Journal of Gastroenterology
2012;59(3):232-238
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: ERCP is the most common procedure for the diagnosis and treatment of bile duct and pancreatic disease, but Post-ERCP pancreatitis makes poor outcome in some cases. The protease inhibitors, nafamostat and gabexate, have been used to prevent pancreatitis related to ERCP, but there is some debate. We tried to evaluate the efficacy of gabexate and nafamostat for the prevention of post-ERCP pancreatitis. METHODS: Two hundred forty two patients (73 patients in the gabexate group, 88 patients in the nafamostat group and 81 patients in the placebo group) were included in the study after selective exclusion. The incidence of pancreatitis after ERCP was compared among groups. RESULTS: The incidence of pancreatitis were 6.8% in the gabexate group, 5.7% in the nafamostat group and 6.2% in the placebo group (p=0.954). CONCLUSIONS: There was no meaningful difference among the gabexate, nafamostat and placebo group.
